SMi Group Ltd.

Competitive advantages of small and large companies and an outlook for the future of the UK generics market

Developing engagement in a regulated environment using the best language to communicate

Improving your infrastructure and better network with the biobanking community

8th annual Asthma & COPD on Monday 16th & Tuesday 17th Apil 2012. Building on the success of our previous Asthma & COPD, and COPD: Novel Therapeutics and Management Strategies events, this year will see an elite panel of Industry speakers.

How to select the most appropriate formulation tool for poorly soluble drugs

Consider solutions to the issues within the current ADC pipeline

Technical developments in Immuno-PET and TKI-PET and their clinical potential

Examining the latest developments in nanomedicine and enhancing in vivo circulation time, extending dissolution kinetics, and improving delivery with drug-porous nanocarriers, lipid-based compounds and biologics.

The state of the European generics market, how will your company make a profit?

With declining R&D costs, prioritizing a portfolio of successful projects has become essential within the pharmaceutical industry. Lifecycle management approaches must be implemented throughout a market period to ensure an increase in profit